1. Home
  2. MRCC vs KRRO Comparison

MRCC vs KRRO Comparison

Compare MRCC & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monroe Capital Corporation

MRCC

Monroe Capital Corporation

N/A

Current Price

$4.68

Market Cap

135.8M

Sector

Finance

ML Signal

N/A

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

N/A

Current Price

$10.61

Market Cap

109.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MRCC
KRRO
Founded
2011
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.8M
109.7M
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
MRCC
KRRO
Price
$4.68
$10.61
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$34.80
AVG Volume (30 Days)
153.7K
199.5K
Earning Date
03-05-2026
03-12-2026
Dividend Yield
7.81%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
181.46
52 Week Low
$4.11
$5.20
52 Week High
$7.92
$55.89

Technical Indicators

Market Signals
Indicator
MRCC
KRRO
Relative Strength Index (RSI) 36.67 43.23
Support Level $4.11 $10.55
Resistance Level $6.77 $14.96
Average True Range (ATR) 0.24 0.87
MACD 0.03 -0.15
Stochastic Oscillator 59.30 2.55

Price Performance

Historical Comparison
MRCC
KRRO

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: